Analysts have raised their price target for Aster DM Healthcare from ₹707 to ₹777, citing expectations of stronger revenue growth and improved profit margins in the future.
What's in the News
- Board meeting scheduled for November 6, 2025, to review unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments)
- The board will consider the adoption of the Aster DM Healthcare Limited Employee Stock Option Scheme 2025 during the upcoming meeting (Key Developments)
- Approval of new registered office premises in the State of Hyderabad is on the board meeting agenda (Key Developments)
- Changes in the composition of committees and the resignation of Non-Executive Director Mr. Anoop Moopen will be considered (Key Developments)
- Final dividend of INR 1 per equity share approved for the financial year ended March 31, 2025 (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has increased from ₹707.11 to ₹777.44, reflecting a positive adjustment in valuation.
- Revenue Growth projection has risen significantly from 37.46% to 53.08%, indicating heightened expectations for future expansion.
- Net Profit Margin estimate has improved from 10.78% to 14.34%, suggesting anticipated operational efficiency gains.
- Future P/E ratio forecast has dropped notably from 47.43x to 28.81x, which points to a more favorable earnings outlook relative to price.
- Discount Rate remains unchanged at 12.76%, indicating a stable risk assessment by analysts.
Have other thoughts on Aster DM Healthcare?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.